Halberd Debt Growth
The Year-over-Year Debt Growth of Halberd (HALB) as of Aug 1, 2026 is 100.00 %. In the previous year, Year-over-Year Debt Growth was -103.69 % — a change of -196.44% (higher).
Get this data via API
Financial Data API
Debt Growth
100.00 %
YoY
-196.44%
Last updated:
Year-over-Year Debt Growth of Halberd is 2026 100.00 % . Year-over-Year Debt Growth of Halberd was 2025 -103.69 % . It decreases by -196.44% higher compared to the previous year.
Access this data via the Eulerpool API
Halberd Stock analysis
What does Halberd do? The Halberd Corp is an American company founded in 1987 and based in New York. It is a high-tech company focused on the development of medical technologies. Since its inception, the company has developed numerous innovative products and technologies that are used worldwide.
A significant portion of Halberd Corp's business model focuses on providing medical products and solutions for various diseases. The main divisions of the company are biotechnology and pharmaceuticals, medical respiratory protection, medical technology, and the development of antibodies and diagnostics.
Some of the most well-known products of Halberd Corp are the Medical Respiratory Masks, which were of great importance during the COVID-19 pandemic. These masks were developed and distributed worldwide by the company with innovative technology and the highest quality standards. The company has also developed various medical devices such as infusion pumps, blood pressure monitors, and various diagnostic devices that have been used by hospitals and care facilities.
Another important business area of Halberd Corp is biotechnology and pharmaceuticals. In this field, the company specializes in developing new drugs and therapies for various diseases. The company has developed a range of proprietary medications that are used in the treatment of various diseases. Halberd Corp is also known for its development of antibodies and diagnostics and offers corresponding test kits.
In recent years, Halberd Corp has formed numerous partnerships with other companies and institutions to bring its innovations to the market and market them. The company is also known for its successful joint ventures with other companies in the healthcare sector.
Overall, Halberd Corp is an innovative company focused on medical technologies. With its presence in various areas of the healthcare industry, the company is able to develop new products and solutions that have the potential to improve and save lives. Halberd is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Halberd stock
Year-over-Year Debt Growth of Halberd is 100.00 % in 2026.
Access this data via the Eulerpool API
Growth — Halberd
Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth
All Key Metrics — Halberd
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth